The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging - 10/10/20
Funding sources: None. |
|
Conflicts of interest: Dr Strober receives honoraria as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Janssen, LEO Pharma, Eli Lilly, Meiji Seika Pharma, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, and Sanofi-Genzyme; is a speaker for AbbVie, Lilly, Janssen, and Ortho Dermatologics; receives a consulting fee as scientific director for the Corrona Psoriasis Registry; is an investigator for Dermavant, AbbVie, the Corrona Psoriasis Registry, Dermira, Cara, and Novartis; and receives an honorarium as Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis. Dr M. Shahriari receives honoraria as a consultant for AbbVie, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, and Regeneron; is a speaker for AbbVie, Lilly, and Janssen; and is an investigator for AbbVie, the Corrona Psoriasis Registry, Dermira, Cara, Dermavant, and Novartis. Dr N. Shahriari has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the author(s). |
Vol 83 - N° 5
P. 1533-1535 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?